nodes	percent_of_prediction	percent_of_DWPC	metapath
Morphine—UGT2B7—Epirubicin—testicular cancer	0.182	0.268	CbGbCtD
Morphine—UGT1A1—Etoposide—testicular cancer	0.123	0.18	CbGbCtD
Morphine—CYP2C8—Ifosfamide—testicular cancer	0.0751	0.111	CbGbCtD
Morphine—ABCB1—Dactinomycin—testicular cancer	0.0431	0.0634	CbGbCtD
Morphine—CYP2C8—Etoposide—testicular cancer	0.0359	0.0528	CbGbCtD
Morphine—CYP3A4—Ifosfamide—testicular cancer	0.0305	0.0448	CbGbCtD
Morphine—ABCB1—Vinblastine—testicular cancer	0.027	0.0397	CbGbCtD
Morphine—CYP2D6—Vinblastine—testicular cancer	0.0254	0.0374	CbGbCtD
Morphine—ABCB1—Cisplatin—testicular cancer	0.0247	0.0364	CbGbCtD
Morphine—ABCB1—Etoposide—testicular cancer	0.0243	0.0358	CbGbCtD
Morphine—ABCB1—Doxorubicin—testicular cancer	0.0166	0.0244	CbGbCtD
Morphine—CYP3A4—Vinblastine—testicular cancer	0.0162	0.0238	CbGbCtD
Morphine—ABCB1—Methotrexate—testicular cancer	0.0161	0.0236	CbGbCtD
Morphine—CYP2D6—Doxorubicin—testicular cancer	0.0156	0.023	CbGbCtD
Morphine—CYP3A4—Etoposide—testicular cancer	0.0146	0.0214	CbGbCtD
Morphine—CYP3A4—Doxorubicin—testicular cancer	0.00993	0.0146	CbGbCtD
Morphine—OPRL1—Peptide ligand-binding receptors—INSL3—testicular cancer	0.000634	0.0666	CbGpPWpGaD
Morphine—UGT1A8—Phase II conjugation—HPGDS—testicular cancer	0.000514	0.054	CbGpPWpGaD
Morphine—UGT2B4—Phase II conjugation—HPGDS—testicular cancer	0.000449	0.0472	CbGpPWpGaD
Morphine—UGT2B15—Phase II conjugation—HPGDS—testicular cancer	0.000449	0.0472	CbGpPWpGaD
Morphine—UGT1A3—NRF2 pathway—SLC2A6—testicular cancer	0.000442	0.0465	CbGpPWpGaD
Morphine—OPRL1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000425	0.0447	CbGpPWpGaD
Morphine—UGT2B7—NRF2 pathway—SLC2A6—testicular cancer	0.000376	0.0395	CbGpPWpGaD
Morphine—OPRL1—GPCR ligand binding—INSL3—testicular cancer	0.000324	0.034	CbGpPWpGaD
Morphine—UGT1A1—NRF2 pathway—SLC2A6—testicular cancer	0.000305	0.0321	CbGpPWpGaD
Morphine—UGT1A8—Biological oxidations—HPGDS—testicular cancer	0.000301	0.0316	CbGpPWpGaD
Morphine—OPRD1—Peptide ligand-binding receptors—INSL3—testicular cancer	0.000271	0.0284	CbGpPWpGaD
Morphine—UGT2B15—Biological oxidations—HPGDS—testicular cancer	0.000263	0.0276	CbGpPWpGaD
Morphine—UGT2B4—Biological oxidations—HPGDS—testicular cancer	0.000263	0.0276	CbGpPWpGaD
Morphine—UGT1A3—Phase II conjugation—HPGDS—testicular cancer	0.000241	0.0253	CbGpPWpGaD
Morphine—OPRK1—Peptide ligand-binding receptors—INSL3—testicular cancer	0.000237	0.0249	CbGpPWpGaD
Morphine—Hyperglycaemia—Doxorubicin—testicular cancer	0.000207	0.000664	CcSEcCtD
Morphine—Nausea—Dactinomycin—testicular cancer	0.000206	0.000662	CcSEcCtD
Morphine—Gastrointestinal pain—Etoposide—testicular cancer	0.000205	0.00066	CcSEcCtD
Morphine—UGT2B7—Phase II conjugation—HPGDS—testicular cancer	0.000205	0.0215	CbGpPWpGaD
Morphine—Drowsiness—Doxorubicin—testicular cancer	0.000204	0.000656	CcSEcCtD
Morphine—Visual impairment—Methotrexate—testicular cancer	0.000204	0.000656	CcSEcCtD
Morphine—Vomiting—Ifosfamide—testicular cancer	0.000202	0.00065	CcSEcCtD
Morphine—Hypersensitivity—Cisplatin—testicular cancer	0.000202	0.000649	CcSEcCtD
Morphine—Bradycardia—Epirubicin—testicular cancer	0.000202	0.000648	CcSEcCtD
Morphine—Renal failure—Doxorubicin—testicular cancer	0.000201	0.000645	CcSEcCtD
Morphine—Rash—Ifosfamide—testicular cancer	0.000201	0.000644	CcSEcCtD
Morphine—OPRM1—Peptide ligand-binding receptors—INSL3—testicular cancer	0.0002	0.0211	CbGpPWpGaD
Morphine—Dermatitis—Ifosfamide—testicular cancer	0.0002	0.000644	CcSEcCtD
Morphine—Urticaria—Etoposide—testicular cancer	0.0002	0.000641	CcSEcCtD
Morphine—Stomatitis—Doxorubicin—testicular cancer	0.000199	0.00064	CcSEcCtD
Morphine—Rhinitis—Epirubicin—testicular cancer	0.000199	0.000638	CcSEcCtD
Morphine—Body temperature increased—Etoposide—testicular cancer	0.000199	0.000638	CcSEcCtD
Morphine—Abdominal pain—Etoposide—testicular cancer	0.000199	0.000638	CcSEcCtD
Morphine—Conjunctivitis—Doxorubicin—testicular cancer	0.000199	0.000638	CcSEcCtD
Morphine—Urinary tract infection—Doxorubicin—testicular cancer	0.000199	0.000638	CcSEcCtD
Morphine—Hepatitis—Epirubicin—testicular cancer	0.000198	0.000637	CcSEcCtD
Morphine—Eye disorder—Methotrexate—testicular cancer	0.000198	0.000636	CcSEcCtD
Morphine—Hypoaesthesia—Epirubicin—testicular cancer	0.000197	0.000634	CcSEcCtD
Morphine—Asthenia—Cisplatin—testicular cancer	0.000197	0.000632	CcSEcCtD
Morphine—Sweating—Doxorubicin—testicular cancer	0.000196	0.000629	CcSEcCtD
Morphine—Urinary tract disorder—Epirubicin—testicular cancer	0.000196	0.000629	CcSEcCtD
Morphine—Oedema peripheral—Epirubicin—testicular cancer	0.000195	0.000627	CcSEcCtD
Morphine—Connective tissue disorder—Epirubicin—testicular cancer	0.000195	0.000626	CcSEcCtD
Morphine—Urethral disorder—Epirubicin—testicular cancer	0.000194	0.000624	CcSEcCtD
Morphine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000193	0.000621	CcSEcCtD
Morphine—Angiopathy—Methotrexate—testicular cancer	0.000192	0.000617	CcSEcCtD
Morphine—Visual impairment—Epirubicin—testicular cancer	0.000191	0.000614	CcSEcCtD
Morphine—Mediastinal disorder—Methotrexate—testicular cancer	0.000191	0.000613	CcSEcCtD
Morphine—Chills—Methotrexate—testicular cancer	0.00019	0.000611	CcSEcCtD
Morphine—Nausea—Ifosfamide—testicular cancer	0.000189	0.000607	CcSEcCtD
Morphine—Diarrhoea—Cisplatin—testicular cancer	0.000188	0.000603	CcSEcCtD
Morphine—Bradycardia—Doxorubicin—testicular cancer	0.000187	0.0006	CcSEcCtD
Morphine—Mental disorder—Methotrexate—testicular cancer	0.000186	0.000596	CcSEcCtD
Morphine—Eye disorder—Epirubicin—testicular cancer	0.000185	0.000595	CcSEcCtD
Morphine—Hypersensitivity—Etoposide—testicular cancer	0.000185	0.000595	CcSEcCtD
Morphine—Erythema—Methotrexate—testicular cancer	0.000184	0.000592	CcSEcCtD
Morphine—Malnutrition—Methotrexate—testicular cancer	0.000184	0.000592	CcSEcCtD
Morphine—Flushing—Epirubicin—testicular cancer	0.000184	0.000591	CcSEcCtD
Morphine—Rhinitis—Doxorubicin—testicular cancer	0.000184	0.000591	CcSEcCtD
Morphine—Hepatitis—Doxorubicin—testicular cancer	0.000183	0.000589	CcSEcCtD
Morphine—OPRL1—GPCR downstream signaling—INSL3—testicular cancer	0.000183	0.0192	CbGpPWpGaD
Morphine—Hypoaesthesia—Doxorubicin—testicular cancer	0.000182	0.000586	CcSEcCtD
Morphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000181	0.0191	CbGpPWpGaD
Morphine—Urinary tract disorder—Doxorubicin—testicular cancer	0.000181	0.000582	CcSEcCtD
Morphine—Oedema peripheral—Doxorubicin—testicular cancer	0.000181	0.00058	CcSEcCtD
Morphine—Dysgeusia—Methotrexate—testicular cancer	0.000181	0.00058	CcSEcCtD
Morphine—Asthenia—Etoposide—testicular cancer	0.00018	0.000579	CcSEcCtD
Morphine—Connective tissue disorder—Doxorubicin—testicular cancer	0.00018	0.000579	CcSEcCtD
Morphine—Angiopathy—Epirubicin—testicular cancer	0.00018	0.000578	CcSEcCtD
Morphine—Urethral disorder—Doxorubicin—testicular cancer	0.00018	0.000578	CcSEcCtD
Morphine—Mediastinal disorder—Epirubicin—testicular cancer	0.000179	0.000574	CcSEcCtD
Morphine—Back pain—Methotrexate—testicular cancer	0.000178	0.000573	CcSEcCtD
Morphine—OPRM1—TCR Signaling Pathway—BCL10—testicular cancer	0.000178	0.0187	CbGpPWpGaD
Morphine—Chills—Epirubicin—testicular cancer	0.000178	0.000571	CcSEcCtD
Morphine—Pruritus—Etoposide—testicular cancer	0.000178	0.000571	CcSEcCtD
Morphine—Visual impairment—Doxorubicin—testicular cancer	0.000177	0.000568	CcSEcCtD
Morphine—Vomiting—Cisplatin—testicular cancer	0.000174	0.00056	CcSEcCtD
Morphine—Vision blurred—Methotrexate—testicular cancer	0.000174	0.000558	CcSEcCtD
Morphine—Mental disorder—Epirubicin—testicular cancer	0.000174	0.000558	CcSEcCtD
Morphine—Rash—Cisplatin—testicular cancer	0.000173	0.000555	CcSEcCtD
Morphine—Dermatitis—Cisplatin—testicular cancer	0.000173	0.000555	CcSEcCtD
Morphine—Erythema—Epirubicin—testicular cancer	0.000173	0.000554	CcSEcCtD
Morphine—Malnutrition—Epirubicin—testicular cancer	0.000173	0.000554	CcSEcCtD
Morphine—Diarrhoea—Etoposide—testicular cancer	0.000172	0.000552	CcSEcCtD
Morphine—Eye disorder—Doxorubicin—testicular cancer	0.000171	0.000551	CcSEcCtD
Morphine—Ill-defined disorder—Methotrexate—testicular cancer	0.000171	0.00055	CcSEcCtD
Morphine—Anaemia—Methotrexate—testicular cancer	0.00017	0.000548	CcSEcCtD
Morphine—Flushing—Doxorubicin—testicular cancer	0.00017	0.000547	CcSEcCtD
Morphine—Flatulence—Epirubicin—testicular cancer	0.00017	0.000546	CcSEcCtD
Morphine—Tension—Epirubicin—testicular cancer	0.000169	0.000544	CcSEcCtD
Morphine—Dysgeusia—Epirubicin—testicular cancer	0.000169	0.000543	CcSEcCtD
Morphine—Nervousness—Epirubicin—testicular cancer	0.000168	0.000538	CcSEcCtD
Morphine—Back pain—Epirubicin—testicular cancer	0.000167	0.000536	CcSEcCtD
Morphine—Angiopathy—Doxorubicin—testicular cancer	0.000166	0.000535	CcSEcCtD
Morphine—Malaise—Methotrexate—testicular cancer	0.000166	0.000534	CcSEcCtD
Morphine—UGT1A1—Phase II conjugation—HPGDS—testicular cancer	0.000166	0.0175	CbGpPWpGaD
Morphine—OPRL1—Signaling by GPCR—INSL3—testicular cancer	0.000166	0.0175	CbGpPWpGaD
Morphine—Dizziness—Etoposide—testicular cancer	0.000166	0.000534	CcSEcCtD
Morphine—Muscle spasms—Epirubicin—testicular cancer	0.000166	0.000533	CcSEcCtD
Morphine—Vertigo—Methotrexate—testicular cancer	0.000166	0.000532	CcSEcCtD
Morphine—Mediastinal disorder—Doxorubicin—testicular cancer	0.000165	0.000531	CcSEcCtD
Morphine—Leukopenia—Methotrexate—testicular cancer	0.000165	0.00053	CcSEcCtD
Morphine—Chills—Doxorubicin—testicular cancer	0.000165	0.000529	CcSEcCtD
Morphine—Nausea—Cisplatin—testicular cancer	0.000163	0.000523	CcSEcCtD
Morphine—Vision blurred—Epirubicin—testicular cancer	0.000163	0.000522	CcSEcCtD
Morphine—Cough—Methotrexate—testicular cancer	0.000161	0.000517	CcSEcCtD
Morphine—Mental disorder—Doxorubicin—testicular cancer	0.000161	0.000516	CcSEcCtD
Morphine—Ill-defined disorder—Epirubicin—testicular cancer	0.00016	0.000514	CcSEcCtD
Morphine—Convulsion—Methotrexate—testicular cancer	0.00016	0.000513	CcSEcCtD
Morphine—Vomiting—Etoposide—testicular cancer	0.00016	0.000513	CcSEcCtD
Morphine—Erythema—Doxorubicin—testicular cancer	0.00016	0.000513	CcSEcCtD
Morphine—Malnutrition—Doxorubicin—testicular cancer	0.00016	0.000513	CcSEcCtD
Morphine—Anaemia—Epirubicin—testicular cancer	0.000159	0.000512	CcSEcCtD
Morphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000159	0.0167	CbGpPWpGaD
Morphine—Agitation—Epirubicin—testicular cancer	0.000159	0.000509	CcSEcCtD
Morphine—Rash—Etoposide—testicular cancer	0.000158	0.000509	CcSEcCtD
Morphine—Dermatitis—Etoposide—testicular cancer	0.000158	0.000508	CcSEcCtD
Morphine—Headache—Etoposide—testicular cancer	0.000157	0.000506	CcSEcCtD
Morphine—Flatulence—Doxorubicin—testicular cancer	0.000157	0.000505	CcSEcCtD
Morphine—Chest pain—Methotrexate—testicular cancer	0.000157	0.000504	CcSEcCtD
Morphine—Arthralgia—Methotrexate—testicular cancer	0.000157	0.000504	CcSEcCtD
Morphine—Tension—Doxorubicin—testicular cancer	0.000157	0.000503	CcSEcCtD
Morphine—Dysgeusia—Doxorubicin—testicular cancer	0.000156	0.000502	CcSEcCtD
Morphine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000156	0.000501	CcSEcCtD
Morphine—Malaise—Epirubicin—testicular cancer	0.000156	0.0005	CcSEcCtD
Morphine—Discomfort—Methotrexate—testicular cancer	0.000155	0.000498	CcSEcCtD
Morphine—Nervousness—Doxorubicin—testicular cancer	0.000155	0.000498	CcSEcCtD
Morphine—Vertigo—Epirubicin—testicular cancer	0.000155	0.000498	CcSEcCtD
Morphine—Syncope—Epirubicin—testicular cancer	0.000155	0.000497	CcSEcCtD
Morphine—Leukopenia—Epirubicin—testicular cancer	0.000154	0.000496	CcSEcCtD
Morphine—Back pain—Doxorubicin—testicular cancer	0.000154	0.000496	CcSEcCtD
Morphine—Muscle spasms—Doxorubicin—testicular cancer	0.000153	0.000493	CcSEcCtD
Morphine—Palpitations—Epirubicin—testicular cancer	0.000152	0.00049	CcSEcCtD
Morphine—Confusional state—Methotrexate—testicular cancer	0.000152	0.000487	CcSEcCtD
Morphine—Loss of consciousness—Epirubicin—testicular cancer	0.000152	0.000487	CcSEcCtD
Morphine—Cough—Epirubicin—testicular cancer	0.000151	0.000484	CcSEcCtD
Morphine—Anaphylactic shock—Methotrexate—testicular cancer	0.00015	0.000483	CcSEcCtD
Morphine—Vision blurred—Doxorubicin—testicular cancer	0.00015	0.000483	CcSEcCtD
Morphine—Convulsion—Epirubicin—testicular cancer	0.000149	0.00048	CcSEcCtD
Morphine—Infection—Methotrexate—testicular cancer	0.000149	0.00048	CcSEcCtD
Morphine—Nausea—Etoposide—testicular cancer	0.000149	0.000479	CcSEcCtD
Morphine—Hypertension—Epirubicin—testicular cancer	0.000149	0.000479	CcSEcCtD
Morphine—Ill-defined disorder—Doxorubicin—testicular cancer	0.000148	0.000476	CcSEcCtD
Morphine—Nervous system disorder—Methotrexate—testicular cancer	0.000148	0.000474	CcSEcCtD
Morphine—Anaemia—Doxorubicin—testicular cancer	0.000148	0.000474	CcSEcCtD
Morphine—Thrombocytopenia—Methotrexate—testicular cancer	0.000147	0.000473	CcSEcCtD
Morphine—Arthralgia—Epirubicin—testicular cancer	0.000147	0.000472	CcSEcCtD
Morphine—Chest pain—Epirubicin—testicular cancer	0.000147	0.000472	CcSEcCtD
Morphine—Agitation—Doxorubicin—testicular cancer	0.000147	0.000471	CcSEcCtD
Morphine—Anxiety—Epirubicin—testicular cancer	0.000146	0.00047	CcSEcCtD
Morphine—Skin disorder—Methotrexate—testicular cancer	0.000146	0.00047	CcSEcCtD
Morphine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000146	0.000469	CcSEcCtD
Morphine—Hyperhidrosis—Methotrexate—testicular cancer	0.000145	0.000467	CcSEcCtD
Morphine—Discomfort—Epirubicin—testicular cancer	0.000145	0.000466	CcSEcCtD
Morphine—Malaise—Doxorubicin—testicular cancer	0.000144	0.000463	CcSEcCtD
Morphine—Dry mouth—Epirubicin—testicular cancer	0.000144	0.000462	CcSEcCtD
Morphine—Vertigo—Doxorubicin—testicular cancer	0.000143	0.000461	CcSEcCtD
Morphine—Anorexia—Methotrexate—testicular cancer	0.000143	0.000461	CcSEcCtD
Morphine—Syncope—Doxorubicin—testicular cancer	0.000143	0.00046	CcSEcCtD
Morphine—Leukopenia—Doxorubicin—testicular cancer	0.000143	0.000459	CcSEcCtD
Morphine—Confusional state—Epirubicin—testicular cancer	0.000142	0.000456	CcSEcCtD
Morphine—Palpitations—Doxorubicin—testicular cancer	0.000141	0.000453	CcSEcCtD
Morphine—Oedema—Epirubicin—testicular cancer	0.000141	0.000452	CcSEcCtD
Morphine—Anaphylactic shock—Epirubicin—testicular cancer	0.000141	0.000452	CcSEcCtD
Morphine—UGT1A3—Biological oxidations—HPGDS—testicular cancer	0.000141	0.0148	CbGpPWpGaD
Morphine—Hypotension—Methotrexate—testicular cancer	0.000141	0.000452	CcSEcCtD
Morphine—Loss of consciousness—Doxorubicin—testicular cancer	0.00014	0.000451	CcSEcCtD
Morphine—Infection—Epirubicin—testicular cancer	0.00014	0.000449	CcSEcCtD
Morphine—Cough—Doxorubicin—testicular cancer	0.000139	0.000448	CcSEcCtD
Morphine—Shock—Epirubicin—testicular cancer	0.000139	0.000445	CcSEcCtD
Morphine—Convulsion—Doxorubicin—testicular cancer	0.000138	0.000444	CcSEcCtD
Morphine—OPRD1—GPCR ligand binding—INSL3—testicular cancer	0.000138	0.0145	CbGpPWpGaD
Morphine—Nervous system disorder—Epirubicin—testicular cancer	0.000138	0.000444	CcSEcCtD
Morphine—Thrombocytopenia—Epirubicin—testicular cancer	0.000138	0.000443	CcSEcCtD
Morphine—Hypertension—Doxorubicin—testicular cancer	0.000138	0.000443	CcSEcCtD
Morphine—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000138	0.0145	CbGpPWpGaD
Morphine—Tachycardia—Epirubicin—testicular cancer	0.000137	0.000442	CcSEcCtD
Morphine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000137	0.00044	CcSEcCtD
Morphine—Skin disorder—Epirubicin—testicular cancer	0.000137	0.000439	CcSEcCtD
Morphine—Hyperhidrosis—Epirubicin—testicular cancer	0.000136	0.000437	CcSEcCtD
Morphine—Insomnia—Methotrexate—testicular cancer	0.000136	0.000437	CcSEcCtD
Morphine—Arthralgia—Doxorubicin—testicular cancer	0.000136	0.000437	CcSEcCtD
Morphine—Chest pain—Doxorubicin—testicular cancer	0.000136	0.000437	CcSEcCtD
Morphine—Anxiety—Doxorubicin—testicular cancer	0.000135	0.000435	CcSEcCtD
Morphine—Paraesthesia—Methotrexate—testicular cancer	0.000135	0.000434	CcSEcCtD
Morphine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000135	0.000434	CcSEcCtD
Morphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000134	0.0141	CbGpPWpGaD
Morphine—Discomfort—Doxorubicin—testicular cancer	0.000134	0.000431	CcSEcCtD
Morphine—Anorexia—Epirubicin—testicular cancer	0.000134	0.000431	CcSEcCtD
Morphine—Dyspnoea—Methotrexate—testicular cancer	0.000134	0.000431	CcSEcCtD
Morphine—Somnolence—Methotrexate—testicular cancer	0.000134	0.00043	CcSEcCtD
Morphine—Dry mouth—Doxorubicin—testicular cancer	0.000133	0.000427	CcSEcCtD
Morphine—Dyspepsia—Methotrexate—testicular cancer	0.000132	0.000426	CcSEcCtD
Morphine—Hypotension—Epirubicin—testicular cancer	0.000132	0.000423	CcSEcCtD
Morphine—Confusional state—Doxorubicin—testicular cancer	0.000131	0.000422	CcSEcCtD
Morphine—Decreased appetite—Methotrexate—testicular cancer	0.000131	0.00042	CcSEcCtD
Morphine—Anaphylactic shock—Doxorubicin—testicular cancer	0.00013	0.000419	CcSEcCtD
Morphine—Oedema—Doxorubicin—testicular cancer	0.00013	0.000419	CcSEcCtD
Morphine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00013	0.000417	CcSEcCtD
Morphine—Fatigue—Methotrexate—testicular cancer	0.00013	0.000417	CcSEcCtD
Morphine—Infection—Doxorubicin—testicular cancer	0.000129	0.000416	CcSEcCtD
Morphine—Pain—Methotrexate—testicular cancer	0.000129	0.000413	CcSEcCtD
Morphine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000128	0.000412	CcSEcCtD
Morphine—Shock—Doxorubicin—testicular cancer	0.000128	0.000412	CcSEcCtD
Morphine—Nervous system disorder—Doxorubicin—testicular cancer	0.000128	0.000411	CcSEcCtD
Morphine—Thrombocytopenia—Doxorubicin—testicular cancer	0.000128	0.00041	CcSEcCtD
Morphine—Insomnia—Epirubicin—testicular cancer	0.000127	0.000409	CcSEcCtD
Morphine—Tachycardia—Doxorubicin—testicular cancer	0.000127	0.000409	CcSEcCtD
Morphine—Skin disorder—Doxorubicin—testicular cancer	0.000127	0.000407	CcSEcCtD
Morphine—Paraesthesia—Epirubicin—testicular cancer	0.000126	0.000406	CcSEcCtD
Morphine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000126	0.000405	CcSEcCtD
Morphine—Dyspnoea—Epirubicin—testicular cancer	0.000126	0.000403	CcSEcCtD
Morphine—Somnolence—Epirubicin—testicular cancer	0.000125	0.000402	CcSEcCtD
Morphine—Anorexia—Doxorubicin—testicular cancer	0.000124	0.000399	CcSEcCtD
Morphine—Feeling abnormal—Methotrexate—testicular cancer	0.000124	0.000398	CcSEcCtD
Morphine—Dyspepsia—Epirubicin—testicular cancer	0.000124	0.000398	CcSEcCtD
Morphine—Gastrointestinal pain—Methotrexate—testicular cancer	0.000123	0.000395	CcSEcCtD
Morphine—Decreased appetite—Epirubicin—testicular cancer	0.000122	0.000393	CcSEcCtD
Morphine—Hypotension—Doxorubicin—testicular cancer	0.000122	0.000391	CcSEcCtD
Morphine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000122	0.000391	CcSEcCtD
Morphine—Fatigue—Epirubicin—testicular cancer	0.000121	0.00039	CcSEcCtD
Morphine—OPRK1—GPCR ligand binding—INSL3—testicular cancer	0.000121	0.0127	CbGpPWpGaD
Morphine—Constipation—Epirubicin—testicular cancer	0.00012	0.000387	CcSEcCtD
Morphine—Pain—Epirubicin—testicular cancer	0.00012	0.000387	CcSEcCtD
Morphine—UGT2B7—Biological oxidations—HPGDS—testicular cancer	0.00012	0.0126	CbGpPWpGaD
Morphine—Urticaria—Methotrexate—testicular cancer	0.00012	0.000384	CcSEcCtD
Morphine—Abdominal pain—Methotrexate—testicular cancer	0.000119	0.000382	CcSEcCtD
Morphine—Body temperature increased—Methotrexate—testicular cancer	0.000119	0.000382	CcSEcCtD
Morphine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000119	0.000381	CcSEcCtD
Morphine—Insomnia—Doxorubicin—testicular cancer	0.000118	0.000379	CcSEcCtD
Morphine—Paraesthesia—Doxorubicin—testicular cancer	0.000117	0.000376	CcSEcCtD
Morphine—Dyspnoea—Doxorubicin—testicular cancer	0.000116	0.000373	CcSEcCtD
Morphine—Feeling abnormal—Epirubicin—testicular cancer	0.000116	0.000373	CcSEcCtD
Morphine—Somnolence—Doxorubicin—testicular cancer	0.000116	0.000372	CcSEcCtD
Morphine—Gastrointestinal pain—Epirubicin—testicular cancer	0.000115	0.00037	CcSEcCtD
Morphine—Dyspepsia—Doxorubicin—testicular cancer	0.000115	0.000368	CcSEcCtD
Morphine—Decreased appetite—Doxorubicin—testicular cancer	0.000113	0.000364	CcSEcCtD
Morphine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000112	0.000361	CcSEcCtD
Morphine—Fatigue—Doxorubicin—testicular cancer	0.000112	0.000361	CcSEcCtD
Morphine—Urticaria—Epirubicin—testicular cancer	0.000112	0.000359	CcSEcCtD
Morphine—Pain—Doxorubicin—testicular cancer	0.000111	0.000358	CcSEcCtD
Morphine—Constipation—Doxorubicin—testicular cancer	0.000111	0.000358	CcSEcCtD
Morphine—Body temperature increased—Epirubicin—testicular cancer	0.000111	0.000358	CcSEcCtD
Morphine—Abdominal pain—Epirubicin—testicular cancer	0.000111	0.000358	CcSEcCtD
Morphine—Hypersensitivity—Methotrexate—testicular cancer	0.000111	0.000356	CcSEcCtD
Morphine—Asthenia—Methotrexate—testicular cancer	0.000108	0.000347	CcSEcCtD
Morphine—Feeling abnormal—Doxorubicin—testicular cancer	0.000107	0.000345	CcSEcCtD
Morphine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000107	0.000342	CcSEcCtD
Morphine—Pruritus—Methotrexate—testicular cancer	0.000106	0.000342	CcSEcCtD
Morphine—Hypersensitivity—Epirubicin—testicular cancer	0.000104	0.000333	CcSEcCtD
Morphine—Urticaria—Doxorubicin—testicular cancer	0.000104	0.000333	CcSEcCtD
Morphine—Body temperature increased—Doxorubicin—testicular cancer	0.000103	0.000331	CcSEcCtD
Morphine—Abdominal pain—Doxorubicin—testicular cancer	0.000103	0.000331	CcSEcCtD
Morphine—Diarrhoea—Methotrexate—testicular cancer	0.000103	0.000331	CcSEcCtD
Morphine—OPRM1—GPCR ligand binding—INSL3—testicular cancer	0.000102	0.0108	CbGpPWpGaD
Morphine—Asthenia—Epirubicin—testicular cancer	0.000101	0.000325	CcSEcCtD
Morphine—Pruritus—Epirubicin—testicular cancer	9.96e-05	0.00032	CcSEcCtD
Morphine—Dizziness—Methotrexate—testicular cancer	9.95e-05	0.00032	CcSEcCtD
Morphine—OPRL1—Signaling Pathways—INSL3—testicular cancer	9.81e-05	0.0103	CbGpPWpGaD
Morphine—UGT1A1—Biological oxidations—HPGDS—testicular cancer	9.72e-05	0.0102	CbGpPWpGaD
Morphine—Diarrhoea—Epirubicin—testicular cancer	9.63e-05	0.00031	CcSEcCtD
Morphine—Hypersensitivity—Doxorubicin—testicular cancer	9.6e-05	0.000308	CcSEcCtD
Morphine—Vomiting—Methotrexate—testicular cancer	9.57e-05	0.000307	CcSEcCtD
Morphine—Rash—Methotrexate—testicular cancer	9.49e-05	0.000305	CcSEcCtD
Morphine—Dermatitis—Methotrexate—testicular cancer	9.48e-05	0.000305	CcSEcCtD
Morphine—Headache—Methotrexate—testicular cancer	9.43e-05	0.000303	CcSEcCtD
Morphine—Asthenia—Doxorubicin—testicular cancer	9.35e-05	0.0003	CcSEcCtD
Morphine—Dizziness—Epirubicin—testicular cancer	9.31e-05	0.000299	CcSEcCtD
Morphine—Pruritus—Doxorubicin—testicular cancer	9.22e-05	0.000296	CcSEcCtD
Morphine—Vomiting—Epirubicin—testicular cancer	8.95e-05	0.000288	CcSEcCtD
Morphine—Nausea—Methotrexate—testicular cancer	8.94e-05	0.000287	CcSEcCtD
Morphine—Diarrhoea—Doxorubicin—testicular cancer	8.91e-05	0.000286	CcSEcCtD
Morphine—Rash—Epirubicin—testicular cancer	8.88e-05	0.000285	CcSEcCtD
Morphine—Dermatitis—Epirubicin—testicular cancer	8.87e-05	0.000285	CcSEcCtD
Morphine—Headache—Epirubicin—testicular cancer	8.82e-05	0.000283	CcSEcCtD
Morphine—Dizziness—Doxorubicin—testicular cancer	8.62e-05	0.000277	CcSEcCtD
Morphine—Nausea—Epirubicin—testicular cancer	8.36e-05	0.000269	CcSEcCtD
Morphine—Vomiting—Doxorubicin—testicular cancer	8.28e-05	0.000266	CcSEcCtD
Morphine—Rash—Doxorubicin—testicular cancer	8.21e-05	0.000264	CcSEcCtD
Morphine—Dermatitis—Doxorubicin—testicular cancer	8.21e-05	0.000264	CcSEcCtD
Morphine—Headache—Doxorubicin—testicular cancer	8.16e-05	0.000262	CcSEcCtD
Morphine—OPRD1—GPCR downstream signaling—INSL3—testicular cancer	7.81e-05	0.00821	CbGpPWpGaD
Morphine—Nausea—Doxorubicin—testicular cancer	7.74e-05	0.000249	CcSEcCtD
Morphine—OPRD1—Signaling by GPCR—INSL3—testicular cancer	7.09e-05	0.00746	CbGpPWpGaD
Morphine—OPRK1—GPCR downstream signaling—INSL3—testicular cancer	6.85e-05	0.0072	CbGpPWpGaD
Morphine—OPRK1—Signaling by GPCR—INSL3—testicular cancer	6.22e-05	0.00654	CbGpPWpGaD
Morphine—OPRM1—GPCR downstream signaling—INSL3—testicular cancer	5.79e-05	0.00608	CbGpPWpGaD
Morphine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	5.59e-05	0.00588	CbGpPWpGaD
Morphine—OPRM1—Signaling by GPCR—INSL3—testicular cancer	5.26e-05	0.00552	CbGpPWpGaD
Morphine—UGT1A8—Metabolism—HPGDS—testicular cancer	5.14e-05	0.0054	CbGpPWpGaD
Morphine—CYP2C8—Biological oxidations—HPGDS—testicular cancer	5.12e-05	0.00538	CbGpPWpGaD
Morphine—UGT2B15—Metabolism—HPGDS—testicular cancer	4.49e-05	0.00472	CbGpPWpGaD
Morphine—UGT2B4—Metabolism—HPGDS—testicular cancer	4.49e-05	0.00472	CbGpPWpGaD
Morphine—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	4.49e-05	0.00472	CbGpPWpGaD
Morphine—CYP2D6—Biological oxidations—HPGDS—testicular cancer	4.2e-05	0.00442	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—INSL3—testicular cancer	4.19e-05	0.0044	CbGpPWpGaD
Morphine—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	4.1e-05	0.00431	CbGpPWpGaD
Morphine—UGT1A8—Metabolism—STK11—testicular cancer	3.74e-05	0.00393	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—INSL3—testicular cancer	3.67e-05	0.00386	CbGpPWpGaD
Morphine—UGT2B4—Metabolism—STK11—testicular cancer	3.26e-05	0.00343	CbGpPWpGaD
Morphine—UGT2B15—Metabolism—STK11—testicular cancer	3.26e-05	0.00343	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—H2AFZ—testicular cancer	3.14e-05	0.0033	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—STK11—testicular cancer	3.12e-05	0.00328	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—INSL3—testicular cancer	3.1e-05	0.00326	CbGpPWpGaD
Morphine—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.98e-05	0.00313	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—KITLG—testicular cancer	2.89e-05	0.00304	CbGpPWpGaD
Morphine—CYP3A4—Biological oxidations—HPGDS—testicular cancer	2.75e-05	0.00289	CbGpPWpGaD
Morphine—UGT1A3—Metabolism—HPGDS—testicular cancer	2.41e-05	0.00253	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—FGFR3—testicular cancer	2.15e-05	0.00226	CbGpPWpGaD
Morphine—UGT2B7—Metabolism—HPGDS—testicular cancer	2.05e-05	0.00215	CbGpPWpGaD
Morphine—OPRL1—Signaling Pathways—KIT—testicular cancer	1.97e-05	0.00207	CbGpPWpGaD
Morphine—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.97e-05	0.00207	CbGpPWpGaD
Morphine—UGT1A3—Metabolism—STK11—testicular cancer	1.75e-05	0.00184	CbGpPWpGaD
Morphine—UGT1A1—Metabolism—HPGDS—testicular cancer	1.66e-05	0.00175	CbGpPWpGaD
Morphine—UGT2B7—Metabolism—STK11—testicular cancer	1.49e-05	0.00156	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—H2AFZ—testicular cancer	1.34e-05	0.00141	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—STK11—testicular cancer	1.33e-05	0.0014	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—KITLG—testicular cancer	1.23e-05	0.0013	CbGpPWpGaD
Morphine—UGT1A1—Metabolism—STK11—testicular cancer	1.21e-05	0.00127	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—H2AFZ—testicular cancer	1.18e-05	0.00124	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—STK11—testicular cancer	1.17e-05	0.00123	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—KITLG—testicular cancer	1.08e-05	0.00114	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—H2AFZ—testicular cancer	9.94e-06	0.00104	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—STK11—testicular cancer	9.88e-06	0.00104	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—FGFR3—testicular cancer	9.17e-06	0.000964	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—KITLG—testicular cancer	9.14e-06	0.000961	CbGpPWpGaD
Morphine—CYP2C8—Metabolism—HPGDS—testicular cancer	8.76e-06	0.000921	CbGpPWpGaD
Morphine—OPRD1—Signaling Pathways—KIT—testicular cancer	8.42e-06	0.000885	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—FGFR3—testicular cancer	8.04e-06	0.000845	CbGpPWpGaD
Morphine—ABCB1—Metabolism—HPGDS—testicular cancer	7.63e-06	0.000802	CbGpPWpGaD
Morphine—OPRK1—Signaling Pathways—KIT—testicular cancer	7.38e-06	0.000776	CbGpPWpGaD
Morphine—CYP2D6—Metabolism—HPGDS—testicular cancer	7.19e-06	0.000756	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—FGFR3—testicular cancer	6.79e-06	0.000714	CbGpPWpGaD
Morphine—CYP2C8—Metabolism—STK11—testicular cancer	6.36e-06	0.000669	CbGpPWpGaD
Morphine—OPRM1—Signaling Pathways—KIT—testicular cancer	6.24e-06	0.000656	CbGpPWpGaD
Morphine—ABCB1—Metabolism—STK11—testicular cancer	5.54e-06	0.000583	CbGpPWpGaD
Morphine—CYP2D6—Metabolism—STK11—testicular cancer	5.22e-06	0.000549	CbGpPWpGaD
Morphine—CYP3A4—Metabolism—HPGDS—testicular cancer	4.7e-06	0.000494	CbGpPWpGaD
Morphine—CYP3A4—Metabolism—STK11—testicular cancer	3.42e-06	0.000359	CbGpPWpGaD
